At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 90 enrolled
Drug / intervention
XOPH5 Ointment +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Double-masked, Placebo-controlled Study of XOPH5 Ointment for Reduction of Lower Lid Steatoblepharon
In Brief
A Phase 2 clinical trial evaluating XOPH5 Ointment and Placebo for Lower Eyelid Steatoblepharon (Excess Eyelid Fat). Completed, enrolled 90 participants across 1 site.
Detailed Summary
This study will test whether XAF5 (XOPH5) ointment, applied once daily to the lower eyelids for 10 weeks, reduces the prominence of lower eyelid fat in adults with moderate to severe steatoblepharon (excess eyelid fat).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartSep 2014
First PostedSep 2014
Primary CompletionDec 2014
TodayJul 2026
First PostedSep 3, 2014
Enrollment StartSep 1, 2014
Primary CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 11.8 years ago
Interventions
XOPH5 Ointmentdrug
Placebodrug